Gene editing may enhance CAR T-cell therapy for hematologic malignancies – Healio
Gene editing may enhance CAR T-cell therapy for hematologic malignancies
Healio … responsible for allogeneic or ‘non-self’ recognition (T-cell receptor/CD3), this would allow us to use ‘off-the-shelf’ third-party T cells from normal donors, thus eliminating any chance of malignant cell contamination and, when infused into an … |